Mathieu, Chantal http://orcid.org/0000-0002-4055-5233
Ahmadzai, Iraj http://orcid.org/0000-0001-9980-6925
Article History
Received: 2 May 2023
Accepted: 20 June 2023
First Online: 8 August 2023
Author’s relationships and activities
: CM serves or has served on the advisory panel for Novo Nordisk, Sanofi, Merck Sharp and Dohme, Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Imcyse, Insulet, Zealand Pharma, Avotres, Mannkind, Sandoz and Vertex. Financial compensation for these activities has been received by KU Leuven. KU Leuven has received research support for CM from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics. CM serves or has served on the speakers’ bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, AstraZeneca and Novartis. Financial compensation for these activities has been received by KU Leuven. CM is President of EASD. All external support of EASD is to be found on ExternalRef removed. IA declares that there are no relationships or activities that might bias, or be perceived to bias, his work.
: Both authors were responsible for drafting the article and revising it critically for important intellectual content. Both authors approved the version to be published.
Free to read: This content has been made available to all.